正电子肿瘤放射药物学：现状与展望。

Cyclotron Radiochemistry Facility, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.

Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Molecules. 2022 Oct 11;27(20):6790. doi: 10.3390/molecules27206790.

Molecular imaging is the visual representation of biological processes that take place at the cellular or molecular level in living organisms. To date, molecular imaging plays an important role in the transition from conventional medical practice to precision medicine. Among all imaging modalities, positron emission tomography (PET) has great advantages in sensitivity and the ability to obtain absolute imaging quantification after corrections for photon attenuation and scattering. Due to the ability to label a host of unique molecules of biological interest, including endogenous, naturally occurring substrates and drug-like compounds, the role of PET has been well established in the field of molecular imaging. In this article, we provide an overview of the recent advances in the development of PET radiopharmaceuticals and their clinical applications in oncology.

分子成像是对活生物体细胞或分子水平上发生的生物学过程的可视化表示。迄今为止，分子成像是将传统医疗实践转变为精准医疗的重要手段。在所有成像方式中，正电子发射断层扫描（PET）在灵敏度和在进行光子衰减和散射校正后获得绝对成像定量的能力方面具有很大的优势。由于能够标记一系列独特的生物感兴趣的分子，包括内源性、天然存在的底物和类药物化合物，因此 PET 在分子成像领域的作用已得到充分确立。在本文中，我们提供了 PET 放射性药物开发的最新进展及其在肿瘤学中的临床应用的概述。